1. ALLA AKTIER
  2. NYHETER
  3. ACTIVE BIOTECH

Active Biotech

Nyheter Active Biotech Nyheter alla bolag

Active Biotech Year End Report 2022

MAR

FOURTH QUARTER IN BRIEF

  • Active Biotech further strengthened the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24)
  • Preclinical data with tasquinimod in MDS presented at ASH 2022 (Dec 13)
  • Phase I Multiple dose study of laquinimod recruited final patient

OTHER SIGNIFICANT EVENTS JAN – DEC 2022

  • Active Biotech appointed Erik Vahtola as Chief Medical Officer (Jan 4)
  • Active Biotech announced first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 7)
  • Active Biotech entered into a global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9)
  • Active Biotech strengthened the patent protection for laquinimod in eye disorders (Apr 26)
  • FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18)
  • Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study started enrolling into the second stage (Jun 1)
  • Active Biotech announced final outcome of the Company’s rights issue (Sep 7)

EVENTS AFTER THE END OF THE PERIOD

  • Preclinical data with tasquinimod published in Journal of Immunotherapy for Cancer
  • Active Biotech confirms positive safety profile of laquinimod eye drops (Jan 30, 2023)

FINANCIAL SUMMARY

SEK MOct-DecJan-Dec

2022 20212022 2021
Net sales––––
Operating profit/loss-15.2-16.1-57.9-49.8
Profit/loss after tax-15.0-16.2-58.4-49.8
Earnings per share (SEK)-0.06-0.07-0.25-0.23
Cash and cash equivalents (at close of period)

41.853.1

The report is also available at www.activebiotech.com

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II-study for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-09 08:30 CET.

Attachments

Active Biotech Year End Report 2022

Datum 2023-02-09, kl 08:30
Källa MFN
Bifogade filer
Active Biotech Year End Report 2022
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet